WO2019152002A1 - Formes posologiques solides orales non extractibles - Google Patents

Formes posologiques solides orales non extractibles Download PDF

Info

Publication number
WO2019152002A1
WO2019152002A1 PCT/US2018/016105 US2018016105W WO2019152002A1 WO 2019152002 A1 WO2019152002 A1 WO 2019152002A1 US 2018016105 W US2018016105 W US 2018016105W WO 2019152002 A1 WO2019152002 A1 WO 2019152002A1
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
extractable
solid dosage
oral solid
particle
Prior art date
Application number
PCT/US2018/016105
Other languages
English (en)
Inventor
Annadurai Dharmarajan
Original Assignee
Dharma Laboratories LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dharma Laboratories LLC filed Critical Dharma Laboratories LLC
Priority to PCT/US2018/016105 priority Critical patent/WO2019152002A1/fr
Publication of WO2019152002A1 publication Critical patent/WO2019152002A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Definitions

  • This invention relates to abuse-deterrent pharmaceutical compositions and dosage forms and manufacturing processes thereof, the compositions comprising an agonist and antagonist that are difficult to separate visually, physically, or chemically.
  • the compositions comprise a tacky amorphous polymer and a crystalline polymer curing agent for the amorphous polymer such that the agonist is releasable and the antagonist is non-releasable unless the dosage forms are tampered with.
  • the non- extractable dosage forms reduce the potential for prescription drug abuse.
  • Opioids are powerful pain killers and are highly addictive. Opioid dependence affects nearly 5 million people in the United States and leads to approximately 17,000 deaths annually. According to the CDC, rates of opioid overdose deaths jumped significantly, from 7.9 per 100,000 in 2013 to 9.0 per 100,000 in 2014, a 14% increase. In 2015, opioid-involved drug overdoses accounted for 33,091 deaths, approximately half involving prescription opioids.
  • Opioid abusers typically tamper with opioid products in order to extract the active drug which is then smoked, inhaled, or injected intravenously (Webster, Pain Med. 70:Sl24 (2009)).
  • the opioids most likely to be abused are those with long- acting (LA) or extended-release (ER) formulations because each tablet or capsule contains approximately 4 times more opioid than their short-acting or immediate- release (IR) counterparts (see Table 1).
  • the active agent in the ER product is extracted for inhalation, smoking, or injection (Katz et al, Am. J. Drug Alcohol Abuse 37: 205 (2011)).
  • One mode of abuse involves crushing a dosage form (e.g., using a pill crusher, coffee grinder, or hammer) and inhaling or snorting the resultant powder.
  • Another mode of abuse involves extracting the active ingredient with water, alcohol or another solvent or heating the drug to transform it into a liquid to produce a liquid form for injection.
  • ADFs abuse-deterrent formulations
  • No. 9,044,398 discloses an abuse deterrent dosage form made by forming micro-particles of a drug modified to increase its lipophilicity.
  • the abuse- deterrent composition retards the release of drug, even if the physical integrity of the formulation is compromised.
  • U.S. Pat. No. 8,420,056 discloses a solid administration form, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances.
  • 9,044,402 discloses a controlled release dosage form using polyethylene oxide (PEO) having an average molecular weight of from about 400,000 daltons to about 600,000 daltons along with opioids such that the tablet composition does not provide immediate release of the opioid even after the abuse-deterrent tablet is subjected to physical tampering selected from crushing, grinding, grating, cutting, or crisping, and wherein the tablet composition exhibits a viscosity of at least 170 mPas.
  • PEO polyethylene oxide
  • U.S. Pat. No. 8,652,529 discloses solid microparticulate oral pharmaceutical forms having a coating layer which assures modified release of the active principle and simultaneously imparts crushing resistance to the coated particles so as to avoid misuse.
  • No. 9,101,661 discloses a controlled release dosage form comprising two different molecular weights of polyethylene oxide and its manufacturing process, by which it is abuse resistant from crushing, alcohol extraction and dose dumping to discourage an abuser from tampering with the dosage form.
  • 8,182,836 discloses an opioid antagonist layer coated on an biologically inert pellet, wherein the opioid antagonist layer comprises a therapeutically effective amount of an opioid antagonist; and a non-releasing membrane coated on the opioid-antagonist layer and other beads that have controlled release agonist.
  • EMBED ATM and TROXYCA ® contain agonist along with the antagonist as capsules.
  • the antagonist is coated on sugar beads and seal coated by a non-permeable polymer and agonist is coated on top of the antagonist beads coat with a permeable polymer.
  • FDA review has indicated that a certain solvent can extract only the agonist and the dosage form can be abused.
  • the solvent extraction effect has been shown in FDA approved naltrexone sequestered products.
  • EMBED ATM contains 0.4 mg of naltrexone/5 mg of morphine and
  • TROXYCA ® has 0.6 mg of naltrexone/5 mg of oxycodone. Based on the oral abuse potential study, the naltrexone concentration in both products does not deter the abuse potential by the oral route.
  • EMBED ATM the antagonist naltrexone, which is sequestered in the core of each bead, remains latent if the drug is taken as prescribed. However, if the beads are crushed, the antagonist is released and reduces the effects of the morphine.
  • a Phase III trial demonstrated efficacy in pain relief. Data released in the abstract indicate that the morphine pharmacokinetic profile of EMBED ATM crushed and swallowed is similar to that of immediate-release morphine, but in liking studies EMBED ATM crushed is“liked” no more than EMBED ATM taken whole. Co-ingestion of alcohol may result in an increase in plasma levels and potentially fatal overdose of morphine.
  • Tablets, capsules, and lozenges are products classified as oral solid dosage forms. They require excipients that are free flowing, so that they can be compressed into tablets without any manufacturing issues of sticking, capping, and quality issues of content uniformity.
  • a typical tableting process involves mixing excipients with drug, and making a granulation using a binder in purified water or a solvent, so that drug is locked with the excipients after drying. It is milled to achieve uniform granule size and blended with glidants and lubricants, which will make the granules flow easily from the hopper to the compression chamber or between the upper and lower compression punches. Once the granules are in the compression chamber, they are compressed into tablets.
  • the present invention uses an amorphous polymer, which is highly tacky and does not flow well.
  • a crystalline polymer is added to convert the tacky amorphous polymer into a non-tacky polymer complex, which makes readily flowable granules after milling, which can be compressed into tablets.
  • Tackifier is added, which re-tackifies the amorphous polymer by heating of the tablets.
  • the tackiness of the amorphous polymer prevents extraction of the drug by solvents and makes the formulation a non-extractable oral solid oral dosage form (NEOSD).
  • the present invention provides a pharmaceutical composition (e.g., NEOSD) that reduces the potential of abuse or misuse of opioids and other drugs of abuse by extraction using home tools and solvents that are commonly used by recreational drug abusers.
  • a pharmaceutical composition e.g., NEOSD
  • Methods to process and manufacture NEOSD formulation are also provided.
  • one aspect of the invention relates to a non-extractable oral solid dosage form comprising two different particles (e.g., granules, spheroids, beads or pellets), the first particle comprising:
  • the second particle comprising:
  • the agonist is releasable and the antagonist is substantially non-releasable upon oral administration of the dosage form.
  • a further aspect of the invention relates to a method of producing the non- extractable oral solid dosage form of the invention, wherein the process comprises: a) preparing the first particle by:
  • a further aspect of the invention relates to a method of decreasing the abuse potential of an agonist active pharmaceutical ingredient oral solid dosage form, the method comprising preparing the non-extractable oral solid dosage form of the invention.
  • An additional aspect of the invention relates to a method of administering an agonist active pharmaceutical ingredient to a subject in need thereof, comprising administering the non-extractable oral solid dosage form of the invention to the subject.
  • Fig. 1 shows an alcohol dose dumping study with extended release hydrocodone bitartrate tablets.
  • Fig. 2 shows an extraction study of crushed tablets with 1 hour dissolution.
  • Fig. 3 shows an extraction study of crushed tablets with 1 hour dissolution.
  • any feature or combination of features set forth herein can be excluded or omitted.
  • the term“about,” as used herein when referring to a measurable value such as an amount of a compound or agent of this invention, dose, time, temperature, and the like, is meant to encompass variations of + 10%, ⁇ 5%,
  • transitional phrase“consisting essentially of’ is to be interpreted as encompassing the recited materials or steps and those that do not materially affect the basic and novel characteristic(s) of the claimed invention.
  • the term“consisting essentially of’ as used herein should not be interpreted as equivalent to“comprising.”
  • “treat,”“treating,” or“treatment of’ it is meant that the severity of the subject’s condition is reduced or at least partially improved or ameliorated and/or that some alleviation, mitigation or decrease in at least one clinical symptom is achieved and/or there is a delay in the progression of the condition.
  • the term“prevent,”“prevents,” or“prevention” refers to a delay in the onset of a disease or disorder or the lessening of symptoms upon onset of the disease or disorder.
  • the terms are not meant to imply complete abolition of disease and encompasses any type of prophylactic treatment that reduces the incidence of the condition or delays the onset and/or progression of the condition.
  • A“treatment effective” amount as used herein is an amount that is sufficient to provide some improvement or benefit to the subject.
  • a “treatment effective” amount is an amount that will provide some alleviation, mitigation, decrease or stabilization in at least one clinical symptom in the subject.
  • the therapeutic effects need not be complete or curative, as long as some benefit is provided to the subject.
  • A“prevention effective” amount as used herein is an amount that is sufficient to prevent and/or delay the onset of a disease, disorder and/or clinical symptoms in a subject and/or to reduce and/or delay the severity of the onset of a disease, disorder and/or clinical symptoms in a subject relative to what would occur in the absence of the methods of the invention.
  • the level of prevention need not be complete, as long as some benefit is provided to the subject.
  • An“agonist,” as used herein, refers to an agent that binds to and activates a receptor to produce a biological effect.
  • An“antagonist,” as used herein, refers to an agent that binds to and inhibits activation of a receptor, e.g., blocks the effect of an agonist on the receptor.
  • the present invention is based on the development of a non-extractable oral solid dosage (NEOSD) pharmaceutical compositions and an antagonist/agonist, two drug combination which will improve patient compliance by alleviating the potential side effects of the opioid drugs.
  • NESD non-extractable oral solid dosage
  • the term“non-extractable” refers to a dosage form in which the agonist cannot be readily removed from the dosage form without also removing the antagonist, i.e., the agonist cannot be readily separated from the antagonist.
  • the NEOSD composition opioid products will reduce the improper tampering, misuse, and abuse of prescription opioid products by recreational abusers.
  • the technology may be useful for other abusable drugs where extended release, controlled release, or immediate release by oral delivery is desired, e.g., for 1 to 4 hour or 12 to 24 hour drug release.
  • the solid oral product is formulated into a matrix tablet using a tacky amorphous polymer and an optionally crystalline active pharmaceutical ingredient (API), and further comprising water insoluble, non- swellable, non-film forming, inert materials.
  • the tacky amorphous polymer is blended with the API and cured with a crystalline polymer curing agent to make it non- tacky and form the dosage form, and then the amorphous polymer is converted back into tacky material, which will hold the API and provide a non-extractable oral solid dosage form.
  • the amorphous polymer is very tacky and is not free flowing so it cannot be made into a tablet.
  • tacy refers to a product that is sufficiently sticky that it is not free flowing and is not suitable for tableting.
  • it is cured with a crystalline polymer it becomes non-tacky and free flowing, and with the drug added along with the channeling agent, it is formed into a dosage form that will release the agonist drug.
  • a similar process is used for the antagonist drug but without the channeling agent, so that the dosage form does not release any of the antagonist.
  • the amorphous polymer surrounding the antagonist is pulled apart and it exposes the antagonist, making the dosage form abuse deterrent.
  • the amorphous polymer used in the invention has very low moisture vapor transmission rate and also is insoluble, making it nearly impossible for any solvent or water to penetrate and make the agonist or antagonist drug soluble for dissolution. This low moisture vapor transmission rate in the amorphous polymers covering the agonist also reduces or eliminates the alcohol dose dumping phenomenon.
  • the NEOSD is formed by a hot-melting process.
  • the formulation contains sensory agents, which will not release from the tablets over a period of 12 or 24 hours, but will be released when the oral dosage form is physically altered.
  • the composition contains additional excipients, e.g., softeners, channelizers, and anti-oxidants.
  • the API release is accompanied by release of the antagonist and/or sensory agents, which deters the snorting, chewing, or injecting of the product to get“high.”
  • the API will release slowly as desired for a period of time, e.g, 1 to 4 hours or 12 to 24 hours.
  • NEOSD extended release opioid drug will improve patient compliance by reducing the opioid tolerance due to the very low release of naltrexone.
  • Burns (Opiate Receptors and Antagonists pp 247-261 (2009)) indicated ultra-low-dose opioid antagonist co-treatment was first shown paradoxically to enhance opioid analgesia and to reduce analgesic tolerance and physical dependence.
  • Naltrexone is an opiate antagonist, a blocker at the endorphin system.
  • LDN Low Dose Naltrexone
  • NEOSD technology uses higher amounts of naltrexone as sequestered, but at the same time, it releases low amounts of naltrexone, where it reduces the opioid tolerance (opioid administration over a period of use forms tolerance, and higher doses have to be administered to relieve pain), so NEOSD release of low doses of naltrexone will improve patient compliance against opioid tolerance.
  • the oral solid dosage form disclosed herein may optionally contain an opioid drug which is free from abuse potential.
  • one aspect of the invention relates to a non-extractable oral solid dosage form comprising, consisting essentially of, or consisting of two different particles, the first particle comprising, consisting essentially of, or consisting of:
  • the second particle comprising, consisting essentially of, or consisting of:
  • the second particle does not comprise a channelizer.
  • the dosage form provides immediate release of the agonist. In some embodiments, the dosage form provides controlled release of the agonist. The dosage form may be adjusted to provide any desirable time frame for release of the agonist, e.g. , 1-4 hours, 4-8 hours, 8-12 hours, 12-24 hours, 24-48 hours, 48-72 hours, or any range therein.
  • the oral solid dosage form may be a unit dosage form, e.g., in any form suitable for oral delivery of a drug, including, without limitation, a tablet, capsule, microcapsule, granule, pellet, lollipop, or lozenge.
  • the dosage form is a tablet.
  • the tablet may be in any format that is suitable for oral delivery of a drug.
  • the tablet is a matrix tablet, e.g., a tablet having a homogenous core which may be coated or uncoated.
  • the first and second particles are intermingled uniformly in the matrix.
  • the tablet is a multilayer tablet, e.g. , a bilayer tablet, in which at least some of the first and second particles are in different layers.
  • the first particle may be in one layer and the second particle in a different layer.
  • one layer may contain both the first and second particle while a different layer contains only the first particle or only the second particle.
  • the layers may also differ in terms of the excipients present.
  • the NEOSD technology of the present invention provides tablets that generally do not break when subjected to typical hardness tests. This may be due to the amorphous polymer forming an integrated tackiness with limited flexibility after curing.
  • the dosage form When measured for tablet hardness using compression force (e.g., using a texture analyzer such as a Brookfield CT3 Texture Analyzer), the dosage form may exhibit a force of at least 6000 g (e.g., at least 8000, 10000, or 12000 g) when compressed to 30% of its thickness.
  • the first particle and the second particle may contain the same tacky amorphous polymer and/or crystalline polymer curing agent.
  • the particles may contain the same tacky amorphous polymer but different crystalline polymer curing agent, the same crystalline polymer curing agent but different tacky amorphous polymers, or different tacky amorphous polymers and different crystalline polymer curing agents.
  • the first and/or second particle may contain two or more different tacky amorphous polymers, e.g, 2, 3, 4, 5 or more different tacky amorphous polymers.
  • the tacky amorphous polymers may be different types of polymers or may be the same polymer but having different average molecular weights.
  • the tacky amorphous polymer in the second particle has a lower molecular weight than the tacky amorphous polymer in the first particle.
  • the first particle may have higher molecular weight amorphous polymers on average than the second particle.
  • the first particle contains a first tacky amorphous polymer having a high molecular weight and a second tacky amorphous polymer having a low molecular weight and/or the second particle contains a first tacky amorphous polymer having a low molecular weight and a second tacky amorphous polymer having a low molecular weight.
  • high molecular weight polymer refers to an average molecular weight range of about 500,000 to about 3,000,000 g/mol and low molecular weight polymer refers to a molecular weight range of about 40,000 to about 400,000.
  • the first and second particles are difficult to separate by any means so that the agonist cannot be separated from the antagonist.
  • the first particle and the second particle cannot be visually
  • the first particle and the second particle cannot be physically or chemically separated, e.g., using a filter or a solvent.
  • any solvent that dissolves the tacky amorphous polymer in the first particle to extract the agonist also dissolves the tacky amorphous polymer in the second particle, thereby extracting the agonist and antagonist together.
  • the NEOSD compositions of the invention are not susceptible to (i.e., eliminate) alcohol-induced dose dumping (ADD) of the agonist.
  • ADD can result in the premature and exaggerated release of a drug. This can greatly increase the concentration of a drug in the body and thereby produce adverse effects or even drug-induced toxicity.
  • the NEOSD compositions of the invention release the agonist in a pH independent fashion, e.g. , independently of the pH of a physiological dissolution medium. This may prevent extraction of the agonist using acids or bases.
  • the agonist in the first particle may be present in any suitable amount to provide a therapeutic or prophylactic effect.
  • the amount of agonist in the first particle is about 0.1 % to about 30% w/w or more of the total dosage form, e.g., about 0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, or any range therein.
  • the agonist may be any API that has a therapeutic or prophylactic effect and which has a known antagonist.
  • the agonist may be one that is susceptible to abuse, e.g., one that is a Drug Enforcement Authority controlled substance.
  • the agonist is a central nervous stimulant, opioid, barbiturate, benzodiazepine, or sedative,
  • the drug or API is crystalline in form.
  • drug and“active pharmaceutical ingredient” are used interchangeably herein to refer to a chemical compound that induces a desired pharmacological, physiological effect.
  • the terms also encompass pharmaceutically acceptable derivatives of those active agents specifically mentioned herein, including, but not limited to, salts, stereoisomers, solvates, hydrates, complexes with one or more molecules, prodrugs, active metabolites, lipophilic derivatives, analogs, and the like.
  • Suitable drugs include, without limitation, amobarbital, alphacetylmethadol, apomorphine, apocedeine, alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, butabarbital, clonitazene, codeine, clonazepam, cycazocaine, cyclophen, cyprenorphine, desomorphine, dextromoramide, dezocine, diazepam, diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene,
  • the antagonist may be present in the dosage form in an amount sufficient to at least partially inhibit, but preferably fully inhibit, the activity of the agonist.
  • the amount of antagonist may be sufficient to inhibit at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% or more of the activity of the agonist.
  • the dosage form may comprise about 0.25 mg to about 5.0 mg of antagonist per 5 mg of agonist, e.g., about 0.25, 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, or 5.0 mg antagonist or any range therein per 5 mg of agonist.
  • the agonist is an opioid and the antagonist is an opioid antagonist.
  • An opioid receptor antagonist is a receptor antagonist that acts on one or more of the opioid receptors.
  • Naloxone and naltrexone are commonly used opioid antagonist drugs which are competitive antagonists that bind to opioid receptors with higher affinity than agonists but do not activate the receptors. This effectively blocks the receptor, preventing the body from responding to opioids.
  • the opioid antagonist may be, without limitation, naloxone, nalmefene, naltrexone, or any other known or later developed opioid receptor antagonist.
  • naloxone and naltrexone are competitive antagonists at the mu, kappa, and delta receptors, with a high affinity for the mu receptor but lacking any mu receptor efficacy.
  • Naltrexone hydrochloride is a pure opioid antagonist. It markedly attenuates or completely blocks, reversibly, the subjective effects of all opioids. When co-administered, on a chronic basis, naltrexone hydrochloride blocks the physical dependence to morphine, heroin and other opioids. Naloxone and naltrexone act centrally and peripherally. Naloxone has low oral bioavailability, but a fast onset of action following parenteral administration.
  • Naltrexone is orally effective with a long duration of action making it useful in abuse deterrent.
  • Nalmefene a mu-opioid receptor antagonist, is a water-soluble naltrexone derivative with a longer duration of action than naloxone.
  • Naltrexone is an orally available semisynthetic opiate antagonist, a synthetic derivate of oxymorphone, approved by the FDA and marketed as REVIA ® with a 50- 150 mg daily dose.
  • Naltrexone and its main active metabolite, 6-beta-naltrexol, are competitive antagonists at mu- and ka-opioid receptors and less at delta-opioid receptors. They reversibly block or significantly attenuate the subjective effects of opioids/classic morphine-like opiates and analgesics with agonist and antagonist activity. Its bioavailability is 5 to 40%. It is well absorbed in the gastrointestinal tract and has a first-pass hepatic metabolism.
  • Plasma protein binding is 21%.
  • the half-life of naltrexone is 4 hours and of 6-beta-naltrexol is 16 hours. It is used in the treatment of heroin and alcohol addiction because it counteracts the effects of opioids by blocking opiate receptors. Dosages range from 25 mg to 150 mg. When blockade is adequate this dose blocks 25 mg heroin administered intravenously.
  • naltrexone is given at a lower dose, equal to or less than 5 mg/day (low-dose naltrexone (LDN)), its opiate antagonist activity turns into an agonist one, so as to trigger a prolonged release of endogenous opioids such as b-endorphins.
  • LDN low-dose naltrexone
  • opiate withdrawal may occur when opiates have been taken 7-10 days prior to the beginning of naltrexone application.
  • Precipitated withdrawal occurs when a full agonist, such as heroin, is displaced from opioid receptors by an antagonist, such as naloxone.
  • Precipitated withdrawal is similar to regular withdrawal but is more intense and has a much faster onset.
  • the order of potency to block analgesia is naltrexone > naloxone > 6b- naltrexol.
  • the order of potency to precipitate withdrawal jumping is naltrexone > naloxone »> 6 -naltrexol.
  • opioid antagonists to reverse the action of opioid agonists
  • Opioid antagonists e.g ., naltrexone and naloxone
  • opioid antagonists have a long clinical history in the management of opioid overdose
  • opioid overdose situations administration of an opioid antagonist can induce an acute withdrawal syndrome that could be life-threatening.
  • the present invention involves a sequestered antagonist such as naltrexone.
  • a sequestered antagonist such as naltrexone.
  • the dosage form When the dosage form is used intact it does not create precipitated withdrawal symptoms due to the antagonist, but releases the agonist to treat pain.
  • NEOSD tablets When NEOSD tablets are crushed, NEOSD will release a sufficient quantity of antagonist to block the euphoria effect of the agonist.
  • the NEOSD composition provides no significant release of the antagonist when the dosage form is administered to a subject intact.
  • no significant release refers to less than 20% of the antagonist released when the intact dosage form undergoes dissolution for 72 hours in 900 ml of purified water, using a paddle (USP apparatus II) at 100 rpm, e.g., less than 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.1% of the antagonist released, e.g., 2% to 20% of the antagonist released.
  • the lack of significant release occurs in dissolution medium of pH 1.2, pH 4.5, or pH 7.0, i.e., independently of pH.
  • the antagonist is naltrexone and less than 0.5 mg or 5% w/w is released over 72 hours when an intact tablet is taken orally, as measured in an in vitro dissolution study in 900 ml of purified water, using a paddle (USP apparatus II) at 100 rpm.
  • Amorphous polymers/viscoelastic polymers do not have any defined shape, or easily altered shape, like a liquid. Polymer chains with branches or irregular pendant groups cannot pack together regularly enough to form crystals. Amorphous regions of a polymer are made up of randomly coiled and entangled chains. They have been compared to a bucket containing a large number of entangled worms - each one 20-feet long and of 1/4-inch thickness. The worms are so tangled that an entire worm cannot slide past the others, but small portions of the worms can twist around within the mass.
  • Amorphous polymers are softer than crystalline polymers and have lower melting points.
  • the temperature and stress state have a profound effect on the molecular arrangement and hence the properties of a polymer. Under the action of sufficient stress, the polymer chains can uncoil and align over a period of time. At elevated temperatures, polymer chains have enough energy to rotate and coil up further.
  • the amorphous polymers used in the invention are inert, insoluble, non- swelling, have a very low moisture vapor transmission rate, lack hardening and provide solvent and chemical resistance. When heated or stress is applied, they change their rheological behaviors.
  • the tacky amorphous polymer is viscoelastic and is hydrophobic, non-gel forming, insoluble, and non-swelling in water, 0.1 N
  • the tacky amorphous polymer has a low glass transition temperature (Tg), e.g., of about -100°C to about l50°C, e.g., about -l00°C, -50°C, 0°C, 50°C, l00°C, or l50°C or any range therein.
  • Tg glass transition temperature
  • the tacky amorphous polymer has a moisture vapor transmission rate of less than 10 g/m 2 /24 h as measured using 2.0 mm film using ASTM F1249, e.g., less than 10, 9, 8, 7, 6, 5, 4, 3, or 2 g/m 2 /24 h.
  • the tacky amorphous polymer is in a semi-crystalline solid state.
  • the molecular weight of the tacky amorphous polymer may be between about 2,500 and about 10,000,000 g/mol, e.g., about 2,500, 5,000, 10,000, 25,000, 50,000, 100,000, 250,000, 500,000, 750,000, 1,000,000, 2,000,000, 3,000,000, 4,000,000, 5,000,000, 6,000,000, 7,000,000, 8,000,00, 9,000,000, or 10,000,000 g/mol or any range therein.
  • the tacky amorphous polymer may be, without limitation, polysiloxane (e.g, silicone, e.g., 20,000 to 8,000,000 g/mol),
  • polyisobutylene e.g, 2500-6,000,000 g/mol
  • polyisoprene polystyrene
  • polysulfone polysulfone
  • copolymers thereof or any combination thereof with molecular weight ranging from 10,000 to 4,000,000 g/mol.
  • the amount of the tacky amorphous polymer in each of the first particle and the second particle is from about 10% to about 75% w/w, e.g, about 20% to about 60% w/w, e.g., about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, or 75%, or any range therein.
  • the amount of the tacky amorphous polymer in each of the first particle and the second particle is the same.
  • the amount of the tacky amorphous polymer in each of the first particle and the second particle is different.
  • the second particle may have less or more of the tacky amorphous polymer than the first particle, e.g, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% less or more or any range therein.
  • the tacky amorphous polymer and the crystalline polymer curing agent are present in a ratio suitable to decrease the tackiness of the amorphous polymer to the point that dosage forms can be prepared.
  • the weight ratio of tacky amorphous polymer to crystalline polymer curing agent is from about 50: 1 to about 1 :50, e.g., about 50:1, 40:1 , 30:1, 20: 1, 10:1, 1 :1, 1 :10, 1 :20, 1 :30, 1 :40, 1 :50, or any range therein.
  • the ratio in each of the first particle and the second particle is the same. In some embodiments, the ratio in each of the first particle and the second particle is different.
  • the crystalline polymer curing agent is a water insoluble, non-film forming, crystalline polymer of natural or synthetic origin and is a solid at room temperature.
  • the ciystalline polymer curing agent has a ring-and-ball softening point above 50°C, e.g. , above 60°C, 70°C, or 80°C.
  • the particles comprise one or more crystalline polymer curing agents, e.g., 2, 3, or 4. Suitable crystalline polymer curing agents include, without limitation, terpene resin, polyvinyl acetate, or a combination thereof.
  • Terpene resins are pale amber, transparent, thermoplastic polyterpene hydrocarbon resins, of the type formula (C l oH] 6 ) n .
  • the terpene resins are supplied either in solid form or in solution in hydrocarbon solvents; the solid forms are made in a wide range of softening points or molecular weights.
  • the commercially available polyterpene resins are produced with a variety of softening points (measured by the ASTM ring-and-ball method E28-51T), ranging from about 10°C to l35°C, corresponding to a range from viscous liquid to hard, brittle solid polymers at ordinary temperatures.
  • the polyterpene has a molecular weight of about 1200 to 4000 g/mol, measured cryoscopically in benzene, a softening point above 70°C, and a melting point above 60°C.
  • Polyvinyl acetate is a colorless, nontoxic, insoluble thermoplastic resin prepared by the polymerization of vinyl acetate. It is used in the molecular weight range of about 15,000 to 150,000 g/mol.
  • the amount of the crystalline polymer curing agent in each of the first particle and the second particle is from about 5% to about 60% w/w, e.g., about 10% to about 40%, e.g, about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, or 60% or any range therein.
  • the amount of the crystalline polymer curing agent in each of the first particle and the second particle is the same.
  • the amount of the crystalline polymer curing agent in each of the first particle and the second particle is different.
  • the second particle may have less or more of the crystalline polymer curing agent than the first particle, e.g. , 5%,
  • the ratio of crystalline polymer curing agent to tacky amorphous polymer is about 1 :1 to about 15: 1, e.g., about 1 :1 to about 10:1, about 1 :1 to about 8: 1, e.g., about 1 :1 to about 5:1.
  • the channelizer may be any agent that is suitable to draw water or another solvent into the first particle to enhance dissolution of the agonist.
  • the channelizers either dissolve themselves (if they are soluble) or direct the solution (if they are insoluble), like dissolution media, through the hydrophobic impermeable amorphous polymer to the agonist for its release. If the channelizer is not added, then the formulation will not release any agonist. Antagonist particles do not have the channelizer, so the dissolution media cannot penetrate and does not release the antagonist drug, so the antagonist part is sequestered in the NEOSD dosage form.
  • Suitable channelizers include, without limitation, electrolytes (e.g., sodium chloride and the like), soluble excipients, dye and insoluble excipients, talc, colloidal silicon dioxide, zinc stearate, magnesium stearate, powdered sugar, lactose, titanium dioxide, aluminum oxide, synthetic wax, carnauba wax, bees wax, paraffin wax, or any combination thereof. In certain embodiments, there may two or more electrolytes (e.g., sodium chloride and the like), soluble excipients, dye and insoluble excipients, talc, colloidal silicon dioxide, zinc stearate, magnesium stearate, powdered sugar, lactose, titanium dioxide, aluminum oxide, synthetic wax, carnauba wax, bees wax, paraffin wax, or any combination thereof. In certain embodiments, there may two or more electrolytes (e.g., sodium chloride and the like), soluble excipients, dye and insoluble excipients, talc, colloidal silicon dioxide
  • channelizers such as colloidal silicon dioxide and talc.
  • the amount of channelizer in the particle may be about 0.1 % to about 25% w/w, e.g., about 1%, to about 15%», e.g., 0.1%, 0.5%, 1%, 5%, 10%, 15%, 20%, or 25%, or any range therein.
  • the channelizer may be present in a ratio to the amorphous polymer of about 1 :20 to about 1 :70 w/w, e.g. , about 1 :20,
  • the channelizer is a very fine insoluble crystalline particle, which serves to channelize the dissolution medium or water into the drug covered polymer.
  • the channelizer is squeezed inside of the tacky amorphous polymer, so less channels are available, thereby less dissolution medium will reach the drug for dissolution and it extracts less drug when the NEOSD tablet is crushed.
  • the tackifying agent may be any agent that causes the amorphous polymer to regain its tackiness (e.g ., modulate the viscoelastic properties of the amorphous polymer).
  • the tackifying agent may be an agent that dissolves in the amorphous polymer and softens and makes the agonist particle non-releasable and the antagonist particle sequestered by making the amorphous polymer in the agonist and antagonist particles stick together.
  • the tackifying agent along with the API, tacky amorphous polymer and crystalline polymer curing agent, forms a tacky and hard tablet.
  • the effect of the tackifying agent on the amorphous polymer is important as it modifies or alters the rheological properties and bring back the tackiness of the amorphous polymer in a controlled manner. After regaining the tackiness or stickiness of the amorphous polymer, this oral solid dosage form becomes non-extractable by physical tempering and solvent extraction.
  • Suitable tackifying agents include, but are not limited to, mineral oil, shellac, polyethylene glycol 200, polyethylene glycol 300, polyethylene glycol 400, polyethylene glycol 540, polyethylene glycol 600, polyethylene glycol 1000, polyethylene glycol 1450, polyethylene glycol 3350, polyethylene glycol 4000, polyethylene glycol 4600, polyethylene glycol 8000, silicone oil, or any combination thereof.
  • the amount of tackifying agent in the particle may be about 0.25% to about 20% w/w, e.g., about 1%, to about 10%, e.g., 0,1%, 0,5%, 1%, 5%, 10%, 15%, or 20%, or any range therein.
  • the amount of the tackifying agent in each of the first particle and the second particle is the same.
  • the amount of the tackifying agent in each of the first particle and the second particle is different.
  • the second particle may have less or more of the tackifying agent than the first particle, e.g., 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% less or more or any range -therein.
  • second particle comprises at least 15% more, e.g., at least 25% more, tackifying agent w/w than the first particle.
  • the dosage form may comprise a sensory agent as a further abuse deterrent.
  • the sensory agent will modify the psychological and/or sensory perception of the dosage form by a subject when the dosage form is physically altered.
  • the sensory agent may be any agent that provides an unpleasant sense, e.g., bitterness, heat, or bad taste.
  • the sensory agent is benzonatate, capsaicin, bittering agent, or any combination thereof.
  • the sensory agent is capsaicin or a derivative thereof.
  • the capsaicin or a derivative thereof e.g. , capsaicinoids
  • substantially no sensory agent is released from the dosage form when it is administered intact, e.g., less than about 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1%, 0.5%, or 0.1%.
  • the sensory agent is capsaicin and substantially no capsaicin is released during dissolution of the dosage form in 40% alcohol in 0.1N HC1 at 50 RPM for 2 hours.
  • the oral dosage form does not significantly release any sensory agent for at least about 12 to 24 hours after oral administration, e.g., at least about 6, 12, 18, 24, 30, 36, 52, or 48 hours after oral administration.
  • the majority of the sensory agent is released from the dosage form when it is tampered with, e.g., ground up. In some embodiments, at least about 50%, 60%, 70%, 80%, or 90% of the sensory agent is released upon tampering with the dosage form. In one embodiment, at least about 70% of capsaicin is released from the dosage form during dissolution of the dosage form in 40% alcohol in 0. IN HC1 at 50 RPM for 2 hours when the dosage form is ground prior to dissolution.
  • the sensory agent may be present in an amount of about 0.1 mg to 15 mg per dosage form, e.g., about 0.1 , 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 mg or any range therein.
  • the sensory agent cannot be separated, isolated, or removed from the dosage form.
  • the sensory agent is present in the dosage form as part of a third particle.
  • the third particle may comprise:
  • a crystalline polymer curing agent for the amorphous polymer ii) a crystalline polymer curing agent for the amorphous polymer; and iii) a softener.
  • the dosage form or the particles within the dosage form may further comprise a lubricant.
  • a lubricant Any suitable lubricant may be used. Examples include, without limitation, stearic acid, polyethylene glycol 8000, or a combination thereof.
  • the amount of the lubricant in each of the first particle and the second particle may be from about 0.5 to about 15% w/w, e.g., about 0.5%, 1%, 5%, 10%, or 15%, or any range therein.
  • the non-extractable oral solid dosage form comprises, consists essentially of, or consists of two different particles
  • the first particle comprising, consisting essentially of, or consisting of:
  • the second particle comprising, consisting essentially of, or consisting of:
  • the dosage form further comprising about 1% to about 20% lubricant.
  • the non-extractable oral solid dosage form comprises, consists essentially of, or consists of two different particles
  • the first particle comprising, consisting essentially of, or consisting of:
  • the second particle comprising, consisting essentially of, or consisting of:
  • talc colloidal silicon dioxide, or camauba wax as the optional channelizer
  • the dosage form further comprising stearic acid as the lubricant.
  • the non-extractable oral solid dosage form comprises, consists essentially of, or consists of two different particles
  • the first particle comprising, consisting essentially of, or consisting of:
  • iii about 1% to about 35% agonist active pharmaceutical ingredient; iv) about 0.1% to about 15% talc, colloidal silicon dioxide, or camauba wax channelizer; and
  • the second particle comprising, consisting essentially of, or consisting of:
  • the dosage form further comprising about 1% to about 20% stearic acid.
  • the non-extractable oral solid dosage forms of the invention deter potential abusers.
  • the dosage form when the dosage form is tampered with, the agonist and antagonist are released together.
  • the dosage form when the dosage form is heated, e.g., when placed in a spoon and the spoon is heated by flame, the dosage form does not form a liquid that can be administered, such as by a syringe. Additionally, when heated, the dosage form does not provide any smoke or vapor for inhalation.
  • One aspect of the invention relates to methods of preparing the non- extractable oral solid dosage forms of the invention.
  • the dosage forms may be prepared by any suitable method known in the art. Suitable methods include, without limitation, a hot-melt process, hot-melt extrusion, or an injection molding process. In one embodiment, the dosage form is produced by a hot-melt process.
  • each particle may be prepared separately by heating the tacky amorphous polymer, adding the active agent and mixing, then adding the additional components to produce a non-tacky and free flowing mixture, and then forming the particles. The particles are then cured such that the amorphous polymer becomes re- tackified.
  • the particles may be combined in a suitable manner and cured at the appropriate stage.
  • the particles may be mixed, cured, and placed in capsules.
  • the particles may be mixed, compressed into tablets, and then cured.
  • each type of particle may be compressed into desired form, the forms compressed together into a tablet, and then cured.
  • the NEOSD antagonist granules are made with the above process and further fluid bed coated with hydrophobic polymers to make the antagonist sequestered.
  • hydrophobic polymers include, without limitation,
  • the hydrophobic polymer is shellac, as it does not form a typical color variation with the antagonist granules.
  • the antagonist granules are prepared by the above method and are filled in capsules containing a sequestered antagonist and releasable agonist granules.
  • the above granules are compressed into bi-layer tablets, containing one layer of antagonist and another layer of agonist, and subsequently coated with an elegant coating using, e.g., Opadry II.
  • the NEOSD is manufactured after melting the polymers and adding the drug (agonist and antagonist) separately and extruding along with the channelizer, then spheronized to form antagonist granules and agonist granules.
  • the NEOSD is manufactured by injection molding, where the amorphous polymer/crystalline polymer along with channelizer and
  • agonist/antagonist is melted and injected into a tablet shape mold as part of a single layer or bi-layer molded tablet.
  • a method of producing the non-extractable oral solid dosage form of the invention comprises:
  • the curing conditions may be any conditions suitable for re-tackifying the amorphous polymer.
  • the curing time is from about 1 hour to about 102 hours, e.g., about 3 hours to about 65 hours, e.g., about 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 hours or any range therein.
  • the curing temperature is about 30°C degrees to about 90°C, e.g., about 35°C to about 65°C, e.g., about 40°C to about 60°C, e.g., about 30°C, 35°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, 70°C, 75°C, 80°C, 85°C, or 90°C or any range therein.
  • the process of making the NEOSD is hot-melt process as follows.
  • tacky amorphous polymer, crystalline polymer curing agent, channelizer, tackifying agent, and crystalline drug opioid/ API are heated above 50°C in a jacketed high shear mixer and after forming a uniform melted blend, the hot melted suspension is cooled in a cooling belt, where the suspension is cooled below l0°C, and the cooled non tacky mass is milled using a suitable Fitzmill fitted with a suitable screen.
  • tacky amorphous polymer, crystalline polymer curing agent, tackifying agent, and antagonist are heated above 50°C in a jacketed high shear mixer and after forming a uniform melted blend, the hot melted suspension is cooled in a cooling belt, where the suspension is cooled below l0°C, and the cooled non tacky mass is milled using a suitable Fitzmill fitted with a suitable screen.
  • the first and second particles are blended together, lubricated and compressed into tablets.
  • the compressed tablets are then cured above 25°C for a few minutes to about 100 hours and optionally film coated for appearance.
  • the viscosity of the amorphous polymer becomes very watery and forms an insoluble barrier surrounding the drug which has the abuse potential, to which is added the channelizer, which directs the water or dissolution media through the insoluble barrier to the drug for its dissolution.
  • the curing agent and the tackifying agent are added. After cooling, the mass become non- tacky and hard. At this stage it can be milled into free flowing granules, which are lubricated during the regular blending process and compressed into a tablets.
  • the tablets after compression the tablets are cured by heat, which makes the amorphous part of the agonist and antagonist particles tacky. This happens in presence of tackifying agent and heat. The melted tackifying agent softens and dissolves part of the amorphous polymer and makes it very tacky or sticky. This process closes the open part of the antagonist granule created during the milling, making the antagonist non-releasable and impossible to isolate or separate antagonist from agonist.
  • the particles and/or the dosage forms may be coated, e.g., with a sustained-release coating, controlled-release coating, or delayed-release coating.
  • a sustained-release coating e.g., with a sustained-release coating, controlled-release coating, or delayed-release coating.
  • Such coatings are particularly useful when the dosage form comprises an opioid antagonist in non-releasable form.
  • the coatings may include a sufficient amount of a hydrophobic material to obtain a weight gain level from about 5% to about 60% to make the antagonist a non-releasable form.
  • Another aspect of the invention relates to methods of administering an agonist active pharmaceutical ingredient to a subject in need thereof, comprising administering the non-extractable oral solid dosage form of the invention to the subject.
  • the dosage form may be administered in therapeutically or prophylactically effective amounts.
  • the agonist is an opioid and the subject is in need of treatment with an opioid, e.g., for treating pain.
  • the dosage forms according to the present invention find use in both veterinary and medical applications. Suitable subjects include both avians and mammals.
  • avian as used herein includes, but is not limited to, chickens, ducks, geese, quail, turkeys, pheasant, parrots, parakeets.
  • mammal as used herein includes, but is not limited to, humans, primates, non-human primates (e.g., monkeys and baboons), cattle, sheep, goats, pigs, horses, cats, dogs, rabbits, rodents (e.g., rats, mice, hamsters, and the like), etc.
  • Human subjects include neonates, infants, juveniles, and adults.
  • the subject is“in need of’ the methods of the present invention, e.g., because the subject has or is believed at risk for a disorder or symptom that would benefit from the delivery of the dosage form of the invention.
  • the subject can be a laboratory animal and/or an animal model of disease.
  • polyisobutylene as the amorphous polymer and polyvinyl acetate as the curing agent.
  • Antagonist granulation
  • Steps 1 and 2 were repeated and oxycodone HC1 API was added to the above blend and mixed for 10 minutes. 8. Steps 4 to 6 were followed.
  • the milled granules were then blended together along with talc and lubricated using stearic acid.
  • the final granules were compressed into tablets using a Rimek Mini II R&D scale compression machine and cured at 30°C.
  • the cured tablets were film coated for elegance.
  • a 20 mg oxycodone formulation (Table 8) was prepared without the tackifying agent in NEOSD tablets.
  • Antagonist granulation
  • Steps 1 and 2 were repeated and oxycodone HC1 API was added to the above blend and mixed for 10 minutes.
  • Steps 4 to 6 are followed 9.
  • the milled granules were then blended together along with talc and lubricated using stearic acid.
  • the final granules were compressed into tablets using a Rimek Mini II R&D scale compression machine and cured at 30°C.
  • the cured tablets were film coated for elegance.
  • Example 1 and Example 2 tablets were crushed using a pill crusher and the crushed tablets were subjected to dissolution at the following settings: Paddle (USP apparatus II) @50 rpm, using 900 mL of Purified water at 37°C +/- 0.5°C , pulled the samples at the end of one hour, the samples were tested using a HPLC test method. The results are shown in FIG. 3.
  • the data from the dissolution test shows that the tablets from Example 1 release less drug compared to the tablets from Example 2, demonstrating that the presence of the tackifying agent makes this NEOSD a non-extractable dosage form.
  • a 20 mg oxycodone formulation (Table 9) is prepared using polysulfone amorphous polymer and polyvinyl acetate as a curing agent.
  • the tablets are prepared by the following procedure.
  • Antagonist granulation
  • Polysulfone is heated above 50°C in a jacketed vessel.
  • Naltrexone HC1 is added to the above blend and mixed for 10 minutes. 4. Polyvinyl acetate is added next and the temperature is maintained above 40°C with stirring for 20 minutes until it forms a homogenous suspension.
  • the above suspension is poured into a cooling chiller belt maintained below lO°C.
  • Steps 1 and 2 are repeated and oxycodone HC1 API is added to the above blend and mixed for 10 minutes.
  • the milled granules are then blended together along with talc and lubricated using stearic acid.
  • the final granules are compressed into tablets using a Rimek Mini II R&D scale compression machine and cured at 30°C.
  • the cured tablets are film coated for elegance.
  • naltrexone release is determined by dissolution testing conducted according to USP Chapter ⁇ 711>.
  • the test uses USP Apparatus II (Paddles) at 100 rpm, 900 mL of water, 37°C. Samples are drawn at 72 hours and assayed by a HPLC assay procedure.
  • the release of oxycodone is determined by dissolution testing conducted according to USP Chapter ⁇ 711>.
  • the test uses USP Apparatus II (Paddles) at 50 rpm, 900 mL of water, 37°C. Samples are drawn at 12 hours and assayed by a HPLC assay procedure. Limit: not less than 85% release at 12 hours.
  • Intact tablets show naltrexone release 5.1% at 72 hours of dissolution and oxycodone meets the above dissolution requirements.
  • the tablets are crushed in a coffee grinder and subjected to dissolution testing with the above parameters for 1 hour of dissolution.
  • the crushed tablets release 89% of the naltrexone.
  • a 10 mg oxymorphone extended release formulation (Table 10) was prepared using polyisobutylene amorphous polymer and terpene resin as a curing agent as capsules.
  • the capsules were prepared by the following procedure.
  • Antagonist granulation
  • Antagonist granules coating
  • Shellac ammonium salt is dispersed in water followed by addition of triethyl citrate as plasticizer.
  • naltrexone antagonist granules were coated using a fluid bed coater fitter with Wurster column with the shellac aqueous solution.
  • Oxymorphone HC1 was added to the above blend and mixed for 10 minutes. 12. Terpene resin was added next and the temperature was maintained above 40°C with stirring for 20 minutes until it formed a homogenous suspension.
  • naltrexone antagonist part and the oxymorphone agonist part granules were blended together with talc and polyethylene glycol as lubricant and filled in a capsule.
  • naltrexone release was determined by dissolution testing conducted according to USP Chapter ⁇ 711>.
  • the test used USP Apparatus II (Paddles) at 100 rpm, 900 mL of water, 37°C. Samples were drawn at 72 hours and assayed by a HPLC assay procedure.
  • Intact tablets showed naltrexone release of 1.92% at 72 hours of dissolution and oxymorphone met the above release criteria.
  • naltrexone granules cannot be separated or isolated as there is no difference in the color of the naltrexone HC1 granules and the oxymorphone HC1 granules, due to the shellac coating. If other hydrophobic coating materials like ethylcellulose or polymethacrylate co-polymers were used it will show as white to off white naltrexone granules, which can be isolated from the
  • the dissolution data of the naltrexone drug release showed release of 0.1152 grams of naltrexone over a period of 72 hours, which is considered sequestration. When used as intact capsules, it will release normally the oxymorphone HC1 to treat pain, but when it is crushed by a coffee grinder or chewed to get high from drug abuse, it will release substantial amounts of naltrexone and act as an antagonist and prevent the drug abuse.
  • a 20 mg hydrocodone bitartrate formulation (Table 11) was prepared using polyisobutylene amorphous polymer and terpene resin as a curing agent with capsaicin as a sensory agent. Table 11
  • Hydrocodone bitartrate was added to the above blend and mixed for 10 minutes.
  • Capsaicin was added to the above and melted together and after forming a homogenous paste, terpene resin was added and the mass poured into a cooling belt and the cooled compacts were milled in a Fitzmill.

Abstract

La présente invention concerne des compositions pharmaceutiques et des formes posologiques anti-abus ainsi que leurs procédés de fabrication, les compositions comprenant un agoniste et un antagoniste qui sont difficiles à séparer visuellement, physiquement ou chimiquement. Les compositions comprennent un polymère amorphe collant et un agent de durcissement de polymère cristallin pour le polymère amorphe de telle sorte que l'agoniste peut être libéré et l'antagoniste ne peut pas être libéré à moins que les formes posologiques ne soient trafiquées. Les formes posologiques non extractibles réduisent la possibilité d'abus de médicament sur ordonnance.
PCT/US2018/016105 2018-01-31 2018-01-31 Formes posologiques solides orales non extractibles WO2019152002A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2018/016105 WO2019152002A1 (fr) 2018-01-31 2018-01-31 Formes posologiques solides orales non extractibles

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2018/016105 WO2019152002A1 (fr) 2018-01-31 2018-01-31 Formes posologiques solides orales non extractibles

Publications (1)

Publication Number Publication Date
WO2019152002A1 true WO2019152002A1 (fr) 2019-08-08

Family

ID=67479811

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/016105 WO2019152002A1 (fr) 2018-01-31 2018-01-31 Formes posologiques solides orales non extractibles

Country Status (1)

Country Link
WO (1) WO2019152002A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032120A1 (fr) * 1997-12-22 1999-07-01 Euro-Celtique, S.A. Procede prevenant l'abus des doses orales d'opioides
EP1492505A2 (fr) * 2002-04-05 2005-01-05 Euro-Celtique S.A. Preparation pharmaceutique contenant oxycodone et naloxone
WO2008086804A2 (fr) * 2007-01-16 2008-07-24 Egalet A/S Utilisation (i) d'un polyglycol et (ii) d'une substance médicamenteuse active dans la préparation d'une composition pharmaceutique destinée (i) à réduire le risque de libération massive induite par l'alcool et/ou (ii) à réduire le risque de toxicomanie médicamenteuse
US20160106839A1 (en) * 2010-09-02 2016-04-21 Grunenthal Gmbh Tamper resistant dosage form comprising inorganic salt

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032120A1 (fr) * 1997-12-22 1999-07-01 Euro-Celtique, S.A. Procede prevenant l'abus des doses orales d'opioides
EP1492505A2 (fr) * 2002-04-05 2005-01-05 Euro-Celtique S.A. Preparation pharmaceutique contenant oxycodone et naloxone
WO2008086804A2 (fr) * 2007-01-16 2008-07-24 Egalet A/S Utilisation (i) d'un polyglycol et (ii) d'une substance médicamenteuse active dans la préparation d'une composition pharmaceutique destinée (i) à réduire le risque de libération massive induite par l'alcool et/ou (ii) à réduire le risque de toxicomanie médicamenteuse
US20160106839A1 (en) * 2010-09-02 2016-04-21 Grunenthal Gmbh Tamper resistant dosage form comprising inorganic salt

Similar Documents

Publication Publication Date Title
CA2913368C (fr) Formulation a liberation immediate empechant les utilisations abusives
AU2007209290B2 (en) Tamper resistant dosage forms
US9603802B2 (en) Extrusion
JP5566102B2 (ja) 医薬組成物
AU2008286914B2 (en) Abuse resistant drugs, method of use and method of making
EP2283816A1 (fr) Formulations opioides administrables par voie orale et obtenues par fusion-extrusion
PT1615615E (pt) Produtos invioláveis para administração de opióides
AU2012347200B2 (en) Tablet capable of combatting misuse by injection
JP2006524249A5 (fr)
UA79069C2 (en) Peroral composition preventing from abuse of opioid agonists contained therein
MXPA04001210A (es) Formulaciones de agonista opioide con antagonista liberable y aislado.
US10624856B2 (en) Non-extractable oral solid dosage forms
WO2019152002A1 (fr) Formes posologiques solides orales non extractibles
AU2011202866B2 (en) Tamper resistant dosage forms

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18903491

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18903491

Country of ref document: EP

Kind code of ref document: A1